NCT05310058已完成不适用
A Randomized, Parallel Study to Assess the Pharmacokinetics of C6 Ketone Di-ester in Healthy Adults
BHB Therapeutics, Ireland LTD2 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2022年4月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- Area under the curve (AUC)
研究概览
简要总结
Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.
详细描述
Recruiting 33 healthy adults to participate in a pharmacokinetic (PK) study of C6 ketone di-ester in a ready to drink beverage matrix. Following randomization, subjects will participate in a full day of PK sample collection prior to being sent home with study product for 1 week. After 1 week of daily consumption, subjects will return to the clinic for a second PK study identical to the first. Blood samples will be collected for 8 hours following test product consumption on both PK days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Outcomes Assessor)
盲法说明
Bioanalytics and biostatistics services will be blinded to treatment identity until after the database has been locked and all analysis is complete.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has a BMI 18.5-34.99 kg/m2 (inclusive)
- •Subject is willing to consume the study beverage daily starting on Day 0 through Day 7 following taste testing at Visit 1
- •Subject is not a smoker and has no plans to change his/her usage of the following products throughout the study period: tobacco, smoking products (including, but not limited to cigarettes, cigars, chewing tobacco, e-cigarettes), and nicotine products (e.g., nicotine gum and/or nicotine patches)
- •Subject is a non-user or former user (cessation ≥3 months) of any marijuana or hemp products and has no plans to use marijuana or hemp products during the study period. No washout is required for topical marijuana or hemp products, but subjects are required to abstain from these products during the study period.
- •Subject is willing and able to comply with all study procedures including overnight fasting (12 ± 2 h, water only), maintenance of usual body weight, avoidance of foods or supplements that increase ketone production in the body throughout the entire study period, avoidance of vigorous exercise (moderate habitual exercise is allowed) with the exception of the 24 h prior to Visits 2 and 3 (Days 0 and 7) when subjects must avoid exercise completely
- •Subjects is willing to abstain from caffeine during Visits 2 and 3 (Days 0 and 7).
- •Subject has a score of 7 to 10 on the Vein Access Scale
- •Subject is willing and able to comply with the visit schedule.
- •Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history, physical examination findings, and routine laboratory test results.
- •Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.
排除标准
- •Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study beverages and all other foods/beverages provided in this study, including soy, milk, and peanut.
- •Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein/low carbohydrate)
- •Subject has used weight-loss medications (including over-the-counter medications and/or supplements) or participated in weight loss programs
- •Unstable use of any prescription medications is not allowed.
- •Subject has used ketone supplements (ketone salts or esters, and medium chain triglycerides [MCT]) within 30 days
- •Subject has been exposed to any non-registered drug product within 30 days of Visit 1
- •Subject has a history or presence of clinically important endocrine (including hyperparathyroidism, type 1 or 2 diabetes mellitus and/or hypoglycemia), cardiovascular (including, but not limited to history of myocardial infarction, peripheral arterial disease, stroke), pulmonary (including uncontrolled asthma), hepatic, renal, gastrointestinal, hematologic, immunologic, dermatologic, rheumatic (including gout), and/or biliary condition(s), that, in the opinion of the Clinical Investigator (has MD qualifications), could interfere with the interpretation of the study results.
- •Subject has a history of bariatric surgery for weight reducing purposes
- •Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- •Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1 (Day -7), at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to Visit 2 (Day 0), for subjects with abnormal laboratory test results.
- •Subject has any signs or symptoms of an active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days of Visit 2 (Day 0). If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved (at the discretion of the Clinical Investigator) and any treatment (e.g., antibiotic therapy) has been completed at least 5 days prior to testing.
- •Subject has experienced any major trauma or any other surgical event within three months
结局指标
主要结局
Area under the curve (AUC)
时间窗: 0 - 8 hours
AUC of circulating metabolites in blood
Cmax
时间窗: 0 - 8 hours
Maximum concentration of circulating metabolites in blood
Tmax
时间窗: 0 - 8 hours
Time to maximum concentration of circulating metabolites in blood
Elimination half-life
时间窗: 0-8 hours
Time required to reduce metabolite concentration by 50%
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Pharmacokinetics of Two Fatty Acid Ketone EstersPharmacokineticsNCT05686083BHB Therapeutics, Ireland LTD12
撤回
1 期
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 MonthsPediatric Gastroesophageal Reflux DiseaseNCT02442752Takeda
已完成
1 期
To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy VolunteersHealthyNCT03445338Sun Pharma Advanced Research Company Limited18
进行中（未招募）
2 期
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeCarcinoid SyndromeCarcinoid TumorCarcinoid Tumor of IleumCarcinoid Tumor of CecumCarcinoid Syndrome DiarrheaCarcinoid Intestine TumorCarcinoid Tumor of LiverCarcinoid Tumor of PancreasCarcinoidNCT05361668Crinetics Pharmaceuticals Inc.36
已完成
3 期
BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma PatientAsthmaNCT05322707Cipla Ltd.1,485